<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03728023</url>
  </required_header>
  <id_info>
    <org_study_id>DZ2018J0001</org_study_id>
    <nct_id>NCT03728023</nct_id>
  </id_info>
  <brief_title>A Study of AZD4205 in Healthy Adult Subjects</brief_title>
  <acronym>JACKPOT2</acronym>
  <official_title>A Phase I, Randomized, Double Blind, Placebo Controlled 2-Parts Study to Assess the Safety, Tolerability, Pharmacokinetics of AZD4205 Following Single and Multiple Ascending Dose in Healthy Adult Subjects, and to Assess the Effect of Food on the Pharmacokinetics of AZD4205</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dizal (Jiangsu) Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dizal (Jiangsu) Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety, tolerability, pharmacokinetics of AZD4205 following
      single and multiple ascending dose in healthy adult subjects, and to assess the effect of
      food on the pharmacokinetics of AZD4205.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 12, 2018</start_date>
  <completion_date type="Actual">August 20, 2019</completion_date>
  <primary_completion_date type="Actual">August 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects with adverse events</measure>
    <time_frame>From screening up to 28 days after last dose (day29 for MAD, day 43 for food effect, day 42 for MAD)</time_frame>
    <description>To evaluate the safety and tolerability of AZD4205 versus placebo in healthy subjects at different dose levels in terms of adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of subjects with abnormal laboratory parameters</measure>
    <time_frame>From screening up to 28 days after last dose (day29 for MAD, day 43 for food effect, day 42 for MAD)</time_frame>
    <description>To evaluate the safety and tolerability of AZD4205 versus placebo in healthy subjects at different dose levels in terms of abnormal laboratory parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of subjects with abnormal vital signs</measure>
    <time_frame>From screening up to 28 days after last dose (day29 for MAD, day 43 for food effect, day 42 for MAD)</time_frame>
    <description>To evaluate the safety and tolerability of AZD4205 versus placebo in healthy subjects at different dose levels in terms of abnormal vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of subjects with abnormal electrocardiogram</measure>
    <time_frame>From screening up to 28 days after last dose (day29 for MAD, day 43 for food effect, day 42 for MAD)</time_frame>
    <description>To evaluate the safety and tolerability of AZD4205 versus placebo in healthy subjects at different dose levels in terms of abnormal electrocardiogram</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>AZD4205</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose: 5mg, 20mg, 50mg, 100mg, 150mg Multiple ascending dose: low, medium and high dose once daily X 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo single dose in SAD and once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD4205</intervention_name>
    <description>SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days</description>
    <arm_group_label>AZD4205</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose in SAD and once daily for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be able to understand the nature of the trial and provide a signed and
             dated, written informed consent form prior to any study specific procedures, sampling
             and analyses.

          2. Female and/or male aged ≥18 ~ ≤ 45 years, with BMI ≥18~≤ 28kg/m2.

          3. Female subjects must have negative pregnancy tests at screening and check-in AND: have
             been surgically sterile OR post-menopausal OR, if of child-bearing potential, must be
             using an acceptable method of contraception.

          4. Male subjects must be surgically sterile or using an acceptable method of
             contraception during the study and for 6 months after the last dose of AZD4205 or
             matching placebo to prevent pregnancy with a partner.

        Exclusion Criteria:

          1. Evidence or reported history of clinically significant hematological (absolute
             neutrophil count &lt; 1.5 x 10^3/μL; platelet count &lt; 100 x 10^3/μL; hemoglobin &lt; 9 g/dL,
             INR &gt; 1.5), renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic,
             psychiatric, neurologic, or allergic disease determined by the investigator.

          2. Infections

          3. Received a live vaccine within 3 months before first dose of IP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory J Tracey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Frontage Clinical Services, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Frontage clinical service</name>
      <address>
        <city>Secaucus</city>
        <state>New Jersey</state>
        <zip>07094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 28, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>July 11, 2020</last_update_submitted>
  <last_update_submitted_qc>July 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

